Cargando…

Nuclear Receptor Subfamily 4A Signaling as a Key Disease Pathway of CD1c+ Dendritic Cell Dysregulation in Systemic Sclerosis

OBJECTIVE: This study was undertaken to identify key disease pathways driving conventional dendritic cell (cDC) alterations in systemic sclerosis (SSc). METHODS: Transcriptomic profiling was performed on peripheral blood CD1c+ cDCs (cDC2s) isolated from 12 healthy donors and 48 patients with SSc, in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Servaas, Nila H., Hiddingh, Sanne, Chouri, Eleni, Wichers, Catharina G. K., Affandi, Alsya J., Ottria, Andrea, Bekker, Cornelis P. J., Cossu, Marta, Silva‐Cardoso, Sandra C., van der Kroef, Maarten, Hinrichs, Anneline C., Carvalheiro, Tiago, Vazirpanah, Nadia, Beretta, Lorenzo, Rossato, Marzia, Bonte‐Mineur, Femke, Radstake, Timothy R. D. J., Kuiper, Jonas J. W., Boes, Marianne, Pandit, Aridaman
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wiley Periodicals, Inc. 2022
Materias:	Systemic Sclerosis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10108054/ https://www.ncbi.nlm.nih.gov/pubmed/36482877 http://dx.doi.org/10.1002/art.42319

Ejemplares similares

Induction of Inflammation and Fibrosis by Semaphorin 4A in Systemic Sclerosis
por: Carvalheiro, Tiago, et al.
Publicado: (2019)

Fatty Acid and Carnitine Metabolism Are Dysregulated in Systemic Sclerosis Patients
por: Ottria, A., et al.
Publicado: (2020)

Characterization of Long Non-Coding RNAs in Systemic Sclerosis Monocytes: A Potential Role for PSMB8-AS1 in Altered Cytokine Secretion
por: Servaas, Nila H., et al.
Publicado: (2021)

Implication of miR-126 and miR-139-5p in Plasmacytoid Dendritic Cell Dysregulation in Systemic Sclerosis
por: Chouri, Eleni, et al.
Publicado: (2021)

Angiopoietin-2 Promotes Inflammatory Activation in Monocytes of Systemic Sclerosis Patients
por: Carvalheiro, Tiago, et al.
Publicado: (2020)

Rituximab in early systemic sclerosis
por: Boonstra, Maaike, et al.
Publicado: (2017)

Transcriptome network analysis implicates CX3CR1-positive type 3 dendritic cells in non-infectious uveitis
por: Hiddingh, Sanne, et al.
Publicado: (2023)

The Long Non-coding RNA NRIR Drives IFN-Response in Monocytes: Implication for Systemic Sclerosis
por: Mariotti, Barbara, et al.
Publicado: (2019)

Update on biomarkers in systemic sclerosis: tools for diagnosis and treatment
por: Affandi, Alsya J., et al.
Publicado: (2015)

Comprehensive analysis of the major histocompatibility complex in systemic sclerosis identifies differential HLA associations by clinical and serological subtypes
por: Acosta-Herrera, Marialbert, et al.
Publicado: (2021)

Transcriptome Analysis of CCR9+ T Helper Cells From Primary Sjögren’s Syndrome Patients Identifies CCL5 as a Novel Effector Molecule
por: Hinrichs, Anneline C., et al.
Publicado: (2021)

A model for interrogating the clinico‐radiological paradox in multiple sclerosis: Internuclear ophthalmoplegia
por: Nij Bijvank, Jenny A., et al.
Publicado: (2021)

Stressful life events are associated with the risk of multiple sclerosis
por: Jiang, X., et al.
Publicado: (2020)

Retinal inter-eye difference and atrophy progression in multiple sclerosis diagnostics
por: Nij Bijvank, Jenny, et al.
Publicado: (2022)

Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group
por: McGuigan, C, et al.
Publicado: (2016)

Editorial: Novel Platform for Antigen Delivery to Dendritic Cells for Immunotherapy
por: Plantinga, Maud, et al.
Publicado: (2022)

Evolution of Systemic Sclerosis–Associated Interstitial Lung Disease One Year After Hematopoietic Stem Cell Transplantation or Cyclophosphamide
por: Ciaffi, Jacopo, et al.
Publicado: (2022)

Memory in multiple sclerosis is linked to glutamate concentration in grey matter regions
por: Muhlert, Nils, et al.
Publicado: (2014)

A 60-year follow-up of the incidence and prevalence of multiple sclerosis in Hordaland County, Western Norway
por: Grytten, N, et al.
Publicado: (2016)

Therapeutic and diagnostic outcomes of a standardised, comprehensive care pathway for patients with systemic sclerosis
por: Meijs, Jessica, et al.
Publicado: (2016)

Incidence and prevalence of multiple sclerosis in the UK 1990–2010: a descriptive study in the General Practice Research Database
por: Mackenzie, I S, et al.
Publicado: (2014)

Adverse events related to biologicals used for patients with multiple sclerosis: a comparison between information originating from regulators and information originating from the scientific community
por: Minnema, L. A., et al.
Publicado: (2020)

Epstein–Barr virus infection after adolescence and human herpesvirus 6A as risk factors for multiple sclerosis
por: Biström, M., et al.
Publicado: (2020)

DIR-visible grey matter lesions and atrophy in multiple sclerosis: partners in crime?
por: van de Pavert, Steven H P, et al.
Publicado: (2016)

T cell composition and polygenic multiple sclerosis risk: A population‐based study in children
por: de Mol, Casper L., et al.
Publicado: (2021)

Contribution of Sex and Autoantibodies to Microangiopathy Assessed by Nailfold Videocapillaroscopy in Systemic Sclerosis: A Systematic Review of the Literature
por: van Leeuwen, Nina M., et al.
Publicado: (2021)

Time matters in multiple sclerosis: can early treatment and long-term follow-up ensure everyone benefits from the latest advances in multiple sclerosis?
por: Cerqueira, João J, et al.
Publicado: (2018)

Characterising the autoantibody repertoire in systemic sclerosis following myeloablative haematopoietic stem cell transplantation
por: Ayoglu, Burcu, et al.
Publicado: (2023)

Failed Degradation of JunB Contributes to Overproduction of Type I Collagen and Development of Dermal Fibrosis in Patients With Systemic Sclerosis
por: Ponticos, Markella, et al.
Publicado: (2015)

Long‐Term Outcomes in Patients With Connective Tissue Disease–Associated Pulmonary Arterial Hypertension in the Modern Treatment Era: Meta‐Analyses of Randomized, Controlled Trials and Observational Registries
por: Khanna, Dinesh, et al.
Publicado: (2021)

Molecular Basis for Dysregulated Activation of NKX2‐5 in the Vascular Remodeling of Systemic Sclerosis
por: Dritsoula, Athina, et al.
Publicado: (2018)

The grey matter correlates of impaired decision-making in multiple sclerosis
por: Muhlert, Nils, et al.
Publicado: (2015)

Factors influencing long-term outcomes in relapsing–remitting multiple sclerosis: PRISMS-15
por: Kappos, Ludwig, et al.
Publicado: (2015)

Structural network disruption markers explain disability in multiple sclerosis
por: Charalambous, Thalis, et al.
Publicado: (2019)

A Multicenter Study of the Validity and Reliability of Responses to Hand Cold Challenge as Measured by Laser Speckle Contrast Imaging and Thermography: Outcome Measures for Systemic Sclerosis–Related Raynaud's Phenomenon
por: Wilkinson, Jack D., et al.
Publicado: (2018)

Efficacy of subcutaneous interferon β-1a on MRI outcomes in a randomised controlled trial of patients with clinically isolated syndromes
por: De Stefano, Nicola, et al.
Publicado: (2014)

Long-term impact of interferon beta-1b in patients with CIS: 8-year follow-up of BENEFIT
por: Edan, G, et al.
Publicado: (2014)

How common is truly benign MS in a UK population?
por: Tallantyre, Emma Clare, et al.
Publicado: (2019)

Progression from suspected to definite systemic sclerosis and the role of anti-topoisomerase I antibodies
por: Liem, Sophie I E, et al.
Publicado: (2023)

Evolution from a first clinical demyelinating event to multiple sclerosis in the REFLEX trial: Regional susceptibility in the conversion to multiple sclerosis at disease onset and its amenability to subcutaneous interferon beta‐1a
por: Battaglini, Marco, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_3grndjmk2f7a1hu8qvve3iqfqf